Press Releases
Gateway Genomics Announces New SneakPeek Early Gender DNA Test Website
Ecommerce company sees sales expand as customers move to online shopping for a fetal sex test that can be taken from the safety of home.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces the launch of an updated website at sneakpeektest.com.
Gateway Genomics Surpasses 200,000 SneakPeek Early Gender DNA Tests Sold with the Acceleration of At-Home Kit Purchases
The prominent sales milestone was achieved last month as families seek alternative proven methods to learn the fetal sex of their babies from the comfort of home.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 200,000 SneakPeek Early Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark in late 2019.
Gateway Genomics Ranks No. 17 in the Inc. 5000 Series: California’s Fastest-Growing Private Companies for 2020
With a two-year revenue increase of 861%, Gateway Genomics emerged as the fastest-growing biotech company in California.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, was recognized in last year’s annual Inc. 5000 list of fastest-growing private companies in the United States.
Gateway Genomics Attends Maternity & Midwifery Festival in London to Expand Market for SneakPeek Clinical Early Gender DNA Test in the UK
Non-invasive prenatal test (NIPT) SneakPeek Clinical identifies fetal sex at 8 weeks gestational age, weeks earlier than any other method.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, attended the 2020 session of the London Maternity & Midwifery Festival in January to share the benefits SneakPeek Clinical can bring to the patients of midwifery professionals.
Gateway Genomics Surpasses 500 Clinical Locations Across the US and UK
Clinical sales revenue continues to accelerate as the company opens SneakPeek to new channels.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, has achieved a milestone of over 500 distributors of its SneakPeek Clinical test across the US and UK. Originally focusing on medical offices, the company has expanded its early gender DNA test offering to independent labs that carry a range of genetic tests.
Gateway Genomics Launches SneakPeek Early Gender DNA Test in Australia
This expansion makes accurate, affordable fetal sex determination at 8 weeks into pregnancy available to Australian families for the first time.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces that the SneakPeek DNA test is now available to Australian mums to learn the gender of their babies as early as 8 weeks into pregnancy.
Gateway Genomics Continues Upward Momentum in Q4 2019 With Over 150,000 SneakPeek Early Gender DNA Tests Sold
The prominent sales milestone was achieved this month as clinical revenue accelerates and the company prepares to launch SneakPeek in Australia.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 150,000 SneakPeek Early Gender DNA Tests sold, just five months after attaining the 100,000-test landmark in June.
Gateway Genomics Attending American College of Osteopathic Obstetricians & Gynecologists (ACOOG) 2019 Fall Conference to Present SneakPeek Clinical Early Gender DNA Test
Non-invasive prenatal test SneakPeek Clinical determines fetal sex at 8 weeks gestational age, weeks to months earlier than any other method.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, will attend the fall 2019 session of ACOOG from October 3-6 in Columbus, OH to share the benefits SneakPeek Clinical can bring to the patients of obstetricians and gynecologists.
Gateway Genomics Ranks 236 in the Inc. 500 Fastest-Growing Private Companies in America List for 2019
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the 38th annual Inc. 500|5000 list of fastest growing private companies, in the first year the company has been eligible to apply. To qualify, companies must have been founded and generating revenue by March 31, 2015. Ranking in the list is determined by the percentage revenue growth from 2015 to 2018, with minimums set for each year. With 1,786% revenue growth from 2015 to 2018, Gateway Genomics ranked #236 in the list, and #23 in the Health sector.
Breakthrough Publication Shows Gateway Genomics SneakPeek Early Gender DNA Blood Test Identifies Fetal Sex at 8 Weeks into Pregnancy with 99.1% Accuracy
Gateway Genomics, a leading developer of genomic tests that give families insight into their future children, announces a new publication titled, “Accurate Fetal Sex Determination from Maternal Blood at 8 Weeks Gestation” in the International Journal of Pregnancy & Child Birth. In the study, DNA blood samples were collected from 108 women at an average gestational age of 8 weeks. Cell-free fetal DNA (cffDNA) was extracted and run through the SneakPeek test process, which looks for male chromosomes. If male chromosomes were detected in the fetal DNA found in mom’s blood, the baby was identified as male. If not, the baby was identified as female. Of 51 male-bearing pregnancies, SneakPeek correctly identified all 51, demonstrating 100% sensitivity for Y-chromosome DNA detection, even at this early stage. Of 57 female-bearing pregnancies, SneakPeek correctly identified 56, leading to a 99.1% accuracy rate for the overall study.